Rituximab cuts autoantibodies to insulin in study

08/18/2011 | HealthDay News

Rituximab treatment worked better than a placebo in suppressing autoantibodies to insulin in patients with new-onset type 1 diabetes, a study in Diabetes found. About 40% of rituximab-treated patients had no IAAs after a year, while no patient on the placebo had the same result, researchers said.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA